inclusion criteria: 1. male or female aged ≥18 years old when signing icf; 2. for subgroup 1 in cohort 1: participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine. the interval between the date of last dose and the date of this study vaccination should be 3 to 24 months. for subgroup 2 in cohort 1: 1) participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine, with or without covid-19 history; or 2) participants who were previously vaccinated with 1 dose of sinopharm inactivated covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. for cohort 2: 1) participants who were previously vaccinated with 2 or 3 doses of mrna covid-19 vaccine (comirnaty or mrna-1273), with or without covid-19 history; or 2) participants who were previously vaccinated with 1 doses of mrna covid-19 vaccine (comirnaty or mrna-1273) and previously diagnosed with covid-19; or 3) participants who were previously not vaccinated with any covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. 3. the participant and/or his legally acceptable representative can sign written icf, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial; 4. the participant and/or his legally acceptable representative have the ability to read, understand, and fill in record cards; 5. healthy participants or participants with pre-existing medical conditions who are in stable condition. the "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. a stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment; 6. fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing icf to 6 months after the study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

inclusion criteria: 1. male or female aged ≥18 years old when signing icf; 2. for subgroup 1 in cohort 1: participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine. the interval between the date of last dose and the date of this study vaccination should be 3 to 24 months. for subgroup 2 in cohort 1: 1) participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine, with or without covid-19 history; or 2) participants who were previously vaccinated with 1 dose of sinopharm inactivated covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. for cohort 2: 1) participants who were previously vaccinated with 2 or 3 doses of mrna covid-19 vaccine (comirnaty or mrna-1273), with or without covid-19 history; or 2) participants who were previously vaccinated with 1 doses of mrna covid-19 vaccine (comirnaty or mrna-1273) and previously diagnosed with covid-19; or 3) participants who were previously not vaccinated with any covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. 3. the participant and/or his legally acceptable representative can sign written icf, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial; 4. the participant and/or his legally acceptable representative have the ability to read, understand, and fill in record cards; 5. healthy participants or participants with pre-existing medical conditions who are in stable condition. the "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. a stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment; 6. fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing icf to 6 months after the study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

inclusion criteria: male or female aged ≥18 years old when signing icf; for subgroup 1 in cohort 1: participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine. the interval between the date of last dose and the date of this study vaccination should be 3 to 24 months. for subgroup 2 in cohort 1: 1) participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine, with or without covid-19 history; or 2) participants who were previously vaccinated with 1 dose of sinopharm inactivated covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. for cohort 2: 1) participants who were previously vaccinated with 2 or 3 doses of mrna covid-19 vaccine (comirnaty or mrna-1273), with or without covid-19 history; or 2) participants who were previously vaccinated with 1 doses of mrna covid-19 vaccine (comirnaty or mrna-1273) and previously diagnosed with covid-19; or 3) participants who were previously not vaccinated with any covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. the participant and/or his legally acceptable representative can sign written icf, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial; the participant and/or his legally acceptable representative have the ability to read, understand, and fill in record cards; healthy participants or participants with pre-existing medical conditions who are in stable condition. the "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. a stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment; fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing icf to 6 months after the study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

inclusion criteria: male or female aged ≥18 years old when signing icf; for subgroup 1 in cohort 1: participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine. the interval between the date of last dose and the date of this study vaccination should be 3 to 24 months. for subgroup 2 in cohort 1: 1) participants who were previously vaccinated with 2 or 3 doses of sinopharm inactivated covid-19 vaccine, with or without covid-19 history; or 2) participants who were previously vaccinated with 1 dose of sinopharm inactivated covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. for cohort 2: 1) participants who were previously vaccinated with 2 or 3 doses of mrna covid-19 vaccine (comirnaty or mrna-1273), with or without covid-19 history; or 2) participants who were previously vaccinated with 1 doses of mrna covid-19 vaccine (comirnaty or mrna-1273) and previously diagnosed with covid-19; or 3) participants who were previously not vaccinated with any covid-19 vaccine and previously diagnosed with covid-19. the interval between the date of last dose/covid-19 diagnosis and the date of this study vaccination should be 3 to 24 months. the participant and/or his legally acceptable representative can sign written icf, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial; the participant and/or his legally acceptable representative have the ability to read, understand, and fill in record cards; healthy participants or participants with pre-existing medical conditions who are in stable condition. the "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. a stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment; fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing icf to 6 months after the study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.